Durvalumab and Tremelimumab for Unresectable Hepatocellular Cancer
Kathryn Green, MSN, ACNP-BC Hepatocellular cancer (HCC) is a common cancer globally, and there are more than 40,000 new cases yearly with an estimated 29,380 deaths per year in the…
Diagnosis & Treatment
Tecvayli: First FDA-Approved Bispecific Antibody for Relapsed/Refractory Multiple Myeloma
Kim Navarrete, MSN, APRN, FNP-C, OCN, and Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP Multiple myeloma (MM) is a hematologic malignancy associated with the clonal proliferation of plasma cells. Despite decades of…
Infectious Complications of Cellular Therapy
Karla V. Ow, MSN, FNP, AOCNP Chimeric antigen receptor (CAR) T cells are lymphocytes that have been genetically modified to produce a CAR that specifically targets tumor cell antigens.1 CAR…
Carvykti: Second FDA-Approved CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP The Food and Drug Administration approved Carvykti (ciltacabtagene autocleucel, Janssen Biotech Inc.) in February 2022 making it the second chimeric antigen receptor (CAR) T-cell therapy…
Our Approach to the Patient With Newly Diagnosed Resectable/Borderline Resectable Pancreatic Adenocarcinoma: From the Medical Oncology Perspective
Amanda Y. Tam, MS, FNP-BC The standard of care with curative intent for resectable or borderline resectable pancreatic adenocarcinoma involves surgery and then adjuvant chemotherapy. High-risk features include the following:…
The Importance of Screening for LUTs in Oncology Patients with CIPN
Lucia Diaz, DNP, ANP-BC, CUNP It is estimated that between 19% and 100% of patients receiving antineoplastic medications known to cause neuropathy may develop chemotherapy-induced peripheral neuropathy (CIPN)1, which may…
Borderline Resectable and Locally Advanced Pancreatic Cancer: Importance of Identification and Treatment
Taylor A. Aldridge, MMS, PA-C Pancreatic ductal adenocarcinoma (PDAC) is a notoriously aggressive gastrointestinal malignancy with an overall 5-year survival rate of 5%.1 This grim prognosis is primarily due to…
TUXEDO-1 Investigators Report High Response Rate in Patients With Brain Metastases From HER2-positive Breast Cancer
The Oncology Connection Fam-trastuzumab-deruxtecan-nxki (Enhertu, Daiichi-Sankyo/AstraZeneca), or T-DXd, led to a high intracranial response rate in patients with active brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast…
Lactic Acidosis in Malignancy: A Rare Oncologic Emergency
Sijimol Mathew, DNP, APRN The patient with cancer has many risk factors for developing lactic acidosis. The diagnosis of cancer itself contributes to the overproduction of lactate caused by thiamine…
Should We Be Worried About Immunotherapy Efficacy in Patients Taking Antibiotics and PPIs?
Beth Sandy, MSN, CRNP Proton pump inhibitors (PPIs) are very common to use in a wide variety of patients to treat many different symptoms of anything from a more serious…